These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 39152688)

  • 21. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH
    Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma cathepsin D as an early indicator of alcohol-related liver disease.
    Li M; Houben T; Bitorina AV; Meesters DM; Israelsen M; Kjærgaard M; Koek GH; Hendrikx T; Verbeek J; Krag A; Thiele M; Shiri-Sverdlov R
    JHEP Rep; 2024 Sep; 6(9):101117. PubMed ID: 39263329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups.
    Li M; Chen W; Deng Y; Xie W
    Nutr Metab Cardiovasc Dis; 2024 Sep; 34(9):2085-2094. PubMed ID: 38902191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study.
    Park Y; Jung J; Han S; Kim GA
    Aliment Pharmacol Ther; 2024 Sep; ():. PubMed ID: 39304991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence.
    Ciardullo S; Mantovani A; Morieri ML; Muraca E; Invernizzi P; Perseghin G
    Liver Int; 2024 Aug; 44(8):1762-1767. PubMed ID: 38597738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
    Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MetALD: Does it require a different therapeutic option?
    Marek GW; Malhi H
    Hepatology; 2024 May; ():. PubMed ID: 38820071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of adiponectin with hepatic steatosis: a study of 1,349 subjects in a random population sample.
    Flechtner-Mors M; George SN; Oeztuerk S; Haenle MM; Koenig W; Imhof A; Boehm BO; Graeter T; Mason RA; Kratzer W; Akinli AS;
    BMC Res Notes; 2014 Apr; 7():207. PubMed ID: 24693952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.
    Kalligeros M; Vassilopoulos A; Vassilopoulos S; Victor DW; Mylonakis E; Noureddin M
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1330-1332.e4. PubMed ID: 37949334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of Steatotic Liver Disease Based on a New Nomenclature in the Japanese Population: A Health Checkup-Based Cross-Sectional Study.
    Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Fukao T; Shimizu M; Yamamoto M
    J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: A single-centre prospective study.
    Sultanik P; Lherault G; Bouzbib C; Ratziu V; Pais R; Mouri S; Thabut D; Rudler M
    Aliment Pharmacol Ther; 2024 Sep; 60(6):796-810. PubMed ID: 39034817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Lee BP; Dodge JL; Terrault NA
    Hepatology; 2024 Mar; 79(3):666-673. PubMed ID: 37732946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
    Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers.
    Muñoz Rossi FA; Salazar Agudelo J; Quinapanta Castro NI; Mosquera SZ; Mejia Fajardo MC; Mosquera López ED; Espitia Olarte JD; Figueroa Medina MA; Zuniga Simancas E; Saldarriaga Osuna LF
    Cureus; 2024 Jun; 16(6):e63019. PubMed ID: 39070357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.